Snyder Capital Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $63.9M | Buy |
281,756
+44,051
| +19% | +$7.84M | 1.1% | 36 |
|
|
2026
Q1 | $41M | Sell |
237,705
-3,258
| -1% | -$604K | 0.8% | 49 |
|
|
2025
Q4 | $48.1M | Buy |
240,963
+63,055
| +35% | +$11.4M | 0.9% | 46 |
|
|
2025
Q3 | $27.8M | Sell |
177,908
-3,199
| -2% | -$508K | 0.53% | 56 |
|
|
2025
Q2 | $27.5M | Buy |
181,107
+6,848
| +4% | +$913K | 0.58% | 56 |
|
|
2025
Q1 | $26.2M | Sell |
174,259
-3,668
| -2% | -$615K | 0.57% | 58 |
|
|
2024
Q4 | $32.8M | Buy |
177,927
+24,086
| +16% | +$4.64M | 0.69% | 50 |
|
|
2024
Q3 | $30.3M | Buy |
153,841
+18,198
| +13% | +$3.78M | 0.63% | 55 |
|
|
2024
Q2 | $28M | Sell |
135,643
-2,503
| -2% | -$567K | 0.63% | 54 |
|
|
2024
Q1 | $37.4M | Sell |
138,146
-9,196
| -6% | -$2.2M | 0.8% | 45 |
|
|
2023
Q4 | $34.8M | Sell |
147,342
-7,492
| -5% | -$1.47M | 0.78% | 47 |
|
|
2023
Q3 | $30.3M | Sell |
154,834
-534
| -0.3% | -$110K | 0.68% | 53 |
|
|
2023
Q2 | $32.7M | Sell |
155,368
-6,980
| -4% | -$1.39M | 0.7% | 52 |
|
|
2023
Q1 | $32.8M | Buy |
162,348
+12,147
| +8% | +$2.75M | 0.7% | 54 |
|
|
2022
Q4 | $32.7M | Sell |
150,201
-2,292
| -2% | -$501K | 0.74% | 51 |
|
|
2022
Q3 | $30M | Sell |
152,493
-3,503
| -2% | -$756K | 0.77% | 50 |
|
|
2022
Q2 | $33.4M | Buy |
155,996
+29,987
| +24% | +$7.33M | 0.9% | 36 |
|
|
2022
Q1 | $35.8M | Buy |
126,009
+3,848
| +3% | +$1.19M | 0.91% | 36 |
|
|
2021
Q4 | $46M | Sell |
122,161
-14,873
| -11% | -$5.78M | 1.11% | 33 |
|
|
2021
Q3 | $56.5M | Buy |
137,034
+18,631
| +16% | +$7.74M | 1.5% | 26 |
|
|
2021
Q2 | $43.8M | Sell |
118,403
-13,329
| -10% | -$4.45M | 1.23% | 30 |
|
|
2021
Q1 | $38.2M | Sell |
131,732
-1,139
| -0.9% | -$317K | 1.1% | 34 |
|
|
2020
Q4 | $33.2M | Sell |
132,871
-943
| -0.7% | -$225K | 1.09% | 35 |
|
|
2020
Q3 | $30.3M | Sell |
133,814
-2,238
| -2% | -$464K | 1.3% | 29 |
|
|
2020
Q2 | $23.7M | Sell |
136,052
-429
| -0.3% | -$68.5K | 1.07% | 31 |
|
|
2020
Q1 | $17.2M | Buy |
136,481
+21,242
| +18% | +$3.19M | 0.98% | 32 |
|
|
2019
Q4 | $17.6M | Buy |
115,239
+31,107
| +37% | +$4.31M | 0.69% | 49 |
|
|
2019
Q3 | $11.1M | Buy |
84,132
+11,687
| +16% | +$1.57M | 0.49% | 58 |
|
|
2019
Q2 | $10.3M | Sell |
72,445
-1,494
| -2% | -$203K | 0.46% | 58 |
|
|
2019
Q1 | $10.7M | Buy |
73,939
+2,835
| +4% | +$372K | 0.51% | 55 |
|
|
2018
Q4 | $8.05M | Sell |
71,104
-5,853
| -8% | -$733K | 0.44% | 58 |
|
|
2018
Q3 | $10.4M | Buy |
76,957
+6,233
| +9% | +$769K | 0.46% | 56 |
|
|
2018
Q2 | $7.94M | Buy |
70,724
+4,765
| +7% | +$515K | 0.38% | 57 |
|
|
2018
Q1 | $7.04M | Sell |
65,959
-1,320
| -2% | -$142K | 0.35% | 56 |
|
|
2017
Q4 | $7.36M | Buy |
67,279
+13,866
| +26% | +$1.51M | 0.37% | 57 |
|
|
2017
Q3 | $5.77M | Sell |
53,413
-2,637
| -5% | -$271K | 0.29% | 57 |
|
|
2017
Q2 | $5.67M | Buy |
+56,050
| New | +$5.16M | 0.3% | 56 |
|
Other funds holding CRL
AI
Snyder Capital Management's CRL Position: Q2 2026 in Review
Snyder Capital Management increased its Charles River Laboratories (CRL) stake by 19% in Q2 2026, buying an estimated $7.84M and bringing the position to 281,756 shares worth $63.9M. The position accounts for 1.1% of the portfolio, ranked #36.
Snyder Capital Management first reported a position in CRL in Q2 2017 and has held it in 37 quarters since. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Snyder Capital Management held 281,756 shares of Charles River Laboratories worth $63.9M as of Q2 2026.
- Snyder Capital Management bought 44,051 Charles River Laboratories shares in Q2 2026, an estimated $7.84M.
- Charles River Laboratories made up 1.1% of Snyder Capital Management's portfolio in Q2 2026, its #36 holding.
- Snyder Capital Management first reported a position in Charles River Laboratories in Q2 2017 and has held it in 37 quarters since.
- 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Snyder Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.